Deals
Valeant Agrees to Buy Egypt Drugmaker Amoun for $800 Million
This article is for subscribers only.
Valeant Pharmaceuticals International Inc. agreed to buy Egyptian drugmaker Amoun Pharmaceutical Co. for $800 million, continuing its torrid pace of dealmaking by expanding further into emerging markets.
Valeant will pay about $800 million plus fees, according to a statement Friday, in its first deal in the Middle East. Amoun, owned by funds run by Capital Group, Concord International Investments and the Rohatyn Group, expects sales of 1.75 billion Egyptian pounds ($223 million) this year, Valeant said.